Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-kappaB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS, RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].
Molecular Weight:
356.80
Purity:
99.46
CAS Number:
[248281-84-7]
Formula:
C19H17ClN2O3
Target:
Apoptosis,NF-kappaB
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
